252 related articles for article (PubMed ID: 24867695)
21. Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells.
Xiao H; Li S; Zhang D; Liu T; Yu M; Wang F
Oncol Rep; 2013 Jan; 29(1):329-34. PubMed ID: 23076497
[TBL] [Abstract][Full Text] [Related]
22. The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Dong YY; Zhuang YH; Cai WJ; Liu Y; Zou WB
Tumour Biol; 2016 Nov; 37(11):15053-15063. PubMed ID: 27658776
[TBL] [Abstract][Full Text] [Related]
23. Leukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose.
Miwa H; Shikami M; Goto M; Mizuno S; Takahashi M; Tsunekawa-Imai N; Ishikawa T; Mizutani M; Horio T; Gotou M; Yamamoto H; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Nitta M
Oncol Rep; 2013 May; 29(5):2053-7. PubMed ID: 23440281
[TBL] [Abstract][Full Text] [Related]
24. Increased sensitivity of an adriamycin-resistant human small cell lung carcinoma cell line to mitochondrial inhibitors.
de Jong S; Holtrop M; de Vries H; de Vries EG; Mulder NH
Biochem Biophys Res Commun; 1992 Jan; 182(2):877-85. PubMed ID: 1310401
[TBL] [Abstract][Full Text] [Related]
25. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.
Somasagara RR; Deep G; Shrotriya S; Patel M; Agarwal C; Agarwal R
Int J Oncol; 2015 Apr; 46(4):1849-57. PubMed ID: 25672620
[TBL] [Abstract][Full Text] [Related]
26. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression.
Maher JC; Savaraj N; Priebe W; Liu H; Lampidis TJ
Pancreas; 2005 Mar; 30(2):e34-9. PubMed ID: 15714127
[TBL] [Abstract][Full Text] [Related]
27. Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Chai X; Chu H; Yang X; Meng Y; Shi P; Gou S
Sci Rep; 2015 Sep; 5():14404. PubMed ID: 26391180
[TBL] [Abstract][Full Text] [Related]
28. The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.
Tesori V; Piscaglia AC; Samengo D; Barba M; Bernardini C; Scatena R; Pontoglio A; Castellini L; Spelbrink JN; Maulucci G; Puglisi MA; Pani G; Gasbarrini A
Sci Rep; 2015 Mar; 5():9149. PubMed ID: 25779766
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.
Dwarkanath BS; Zolzer F; Chandana S; Bauch T; Adhikari JS; Muller WU; Streffer C; Jain V
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1051-61. PubMed ID: 11429233
[TBL] [Abstract][Full Text] [Related]
30. Berberine combined with 2-deoxy-d-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption.
Fan LX; Liu CM; Gao AH; Zhou YB; Li J
Biochim Biophys Acta; 2013 Nov; 1830(11):5175-83. PubMed ID: 23872355
[TBL] [Abstract][Full Text] [Related]
31. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death.
Cheng G; Zielonka J; Dranka BP; McAllister D; Mackinnon AC; Joseph J; Kalyanaraman B
Cancer Res; 2012 May; 72(10):2634-44. PubMed ID: 22431711
[TBL] [Abstract][Full Text] [Related]
32. Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Ma M; Ma C; Li P; Ma C; Ping F; Li W; Xu L; Zhang H; Sun Q; Li Y
Cell Cycle; 2020 Sep; 19(17):2168-2181. PubMed ID: 32718270
[TBL] [Abstract][Full Text] [Related]
33. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Wang K; Baldwin GS; Nikfarjam M; He H
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
[TBL] [Abstract][Full Text] [Related]
35. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
36. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
37. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
38. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Lev-Ari S; Zinger H; Kazanov D; Yona D; Ben-Yosef R; Starr A; Figer A; Arber N
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S276-80. PubMed ID: 16507392
[TBL] [Abstract][Full Text] [Related]
39. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Kawanami T; Takiguchi S; Ikeda N; Funakoshi A
Oncol Rep; 2012 Mar; 27(3):867-72. PubMed ID: 22200743
[TBL] [Abstract][Full Text] [Related]
40. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
